Journal
MARINE DRUGS
Volume 11, Issue 9, Pages 3258-3271Publisher
MDPI AG
DOI: 10.3390/md11093258
Keywords
pseudopterosins; log P; human umbilical vein endothelial cells (HUVEC); proliferation; hydroxypropyl-beta-cyclodextrin (HPCD)
Categories
Funding
- United States Army Medical Research and Materiel Command [W81XWH-06-1-0089]
- UCSB Academic Senate
Ask authors/readers for more resources
Pseudopterosin A (PsA) treatment of growth factor depleted human umbilical vein endothelial cell (HUVEC) cultures formulated in hydroxypropyl--cyclodextrin (HPCD) for 42 h unexpectedly produced a 25% increase in cell proliferation (EC50 = 1.34 x 10(-8) M). Analysis of dose response curves revealed pseudo-first order saturation kinetics, and the uncoupling of cytotoxicity from cell proliferation, thereby resulting in a widening of the therapeutic index. The formulation of PsA into HPCD produced a 200-fold increase in potency over a DMSO formulation; we propose this could result from a constrained presentation of PsA to the receptor, which would limit non-specific binding. These results support the hypothesis that the non-specific receptor binding of PsA when formulated in DMSO has ostensibly masked prior estimates of specific activity, potency, and mechanism. Collectively, these results suggest that the formulation of PsA and compounds of similar chemical properties in HPCD could result in significant pharmacological findings that may otherwise be obscured when using solvents such as DMSO.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available